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Background-—The effectiveness of radial access (RA) in ST-elevation myocardial infarction (STEMI) has been predominantly
established in primary percutaneous coronary intervention (pPCI) with limited exploration of this issue in the early postﬁbrinolytic
patient. The purpose of this study was to compare the effectiveness and safety of RA versus femoral (FA) access in STEMI
undergoing either a pharmacoinvasive (PI) strategy or pPCI.
Methods and Results-—Within STrategic Reperfusion Early After Myocardial Infarction (STREAM), we evaluated the relationship
between arterial access site and primary outcome (30-day composite of death, shock, congestive heart failure, or reinfarction) and
major bleeding according to the treatment strategy received. A total of 1820 STEMI patients were included: 895 PI (49.2%; rescue
PCI [n=379; 42.3%], scheduled PCI [n=516; 57.7%]) and 925 pPCI (50.8%). Irrespective of treatment strategy, there was
comparable utilization of either access site (FA: PI 53.4% and pPCI 57.6%). FA STEMI patients were younger, had lower presenting
systolic blood pressure, lesser Thrombolysis In Myocardial Infarction risk, and more ∑ST-elevation at baseline. The primary
composite endpoint occurred in 8.9% RA versus 15.7% FA patients (P<0.001). On multivariable analysis, this beneﬁt on the primary
composite outcome favoring RA persisted (adjusted odds ratio [OR], 0.59; 95% CI, 0.44–0.78; P<0.001) and was evident in both
pPCI (adjusted OR, 0.63; 95% CI, 0.43–0.92) and PI cohorts (adjusted OR, 0.57 95% CI, 0.37–0.86; P interaction=0.730). There was
no difference in nonintracranial major bleeding with either access group (RA vs FA, 5.2% vs 6.0%; P=0.489).
Conclusions-—Regardless of the application of a PI or pPCI strategy, RA was associated with improved clinical outcomes,
supporting current STEMI evidence in favor of RA in PCI.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT00623623. ( J Am Heart Assoc. 2016;5:
e003559 doi: 10.1161/JAHA.116.003559)
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T he utilization of radial (RA) over femoral arterial access(FA) for acute coronary intervention in ST-elevation
myocardial infarction (STEMI) is supported by a reduction in
mortality, ischemic, and bleeding endpoints.1–8 This has led
various interventional societies to encourage its utilization
over femoral access.9–11 Although the basis of this evidence
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includes patients undergoing both primary and rescue percu-
taneous coronary intervention (PCI), the majority of random-
ized data are conﬁned to patients treated with primary PCI
(pPCI).2,7 RA in patients treated with a ﬁbrinolytic pharma-
coinvasive strategy (PI) has had limited exploration,12–14 as
has any direct comparison with patients treated with pPCI.
Moreover, the application of a PI strategy creates at least 2
distinct patient subsets at the time of angiography, each with
a different risk proﬁle with respect to ischemic outcomes and
major bleeding/access-site complications.15 The ﬁrst is the
“nonreperfused” patient requiring urgent rescue PCI who has
received recent ﬁbrinolysis with adjunctive antithrombotic
and antiplatelet therapy sometimes associated with hemody-
namic or electrical instability. The second is the stable
“reperfused” STEMI undergoing scheduled PCI 6 to 24 hours
later. Intuitively, a comparable efﬁcacy and safety advantage
—as observed in pPCI in favor of RA—is expected in patients
treated with a PI strategy, particularly in the subset under-
going rescue PCI.
The STrategic Reperfusion Early After Myocardial infarction
(STREAM) trial,16 which randomized patients to a ﬁbrinolytic
PI (rescue and scheduled PCI) versus pPCI treatment strategy,
provided a unique opportunity to address this issue in an early
presenting, rapidly treated contemporary STEMI cohort.
Accordingly, within STREAM, we evaluated the relationship
between arterial access site and the 30-day primary compos-
ite (all cause death, shock, congestive heart failure [CHF], and
reinfarction) as well as major bleeding events in STEMI
according to the treatment strategy received.
Methods
Study Design and Patient Population
The STREAM trial protocol and primary results have been
published previously.16,17 The study protocol was approved by
national regulatory authorities and by the local ethics
committee at each study center. All patients provided written
informed consent. In brief, acute STEMI patients presenting
within 3 hours of symptom onset and unable to undergo pPCI
within 1 hour of ﬁrst medical contact were randomized to
either ﬁbrinolysis with a protocol-deﬁned PI strategy or pPCI.
In the PI strategy, bolus weight-based tenecteplase (TNK),
aspirin, clopidogrel, and enoxaparin were administered accord-
ing to guideline recommendations and followed by either
rescue PCI or scheduled angiography (within 6–24 hours).
After 21% of the ultimate population had been enrolled, the
executive committee amended the protocol on August 24,
2009, to reduce the dose of TNK by 50% in patients 75 years
of age or older because of an excess of intracranial hemor-
rhage (ICH) in that age group. The need for rescue PCI was
determined by site investigators according to <50% ST
segment resolution in the electrocardiogram (ECG) lead with
the maximal ST-elevation 90 minutes after TNK bolus, hemo-
dynamic instability, or refractory ventricular arrhythmias as
mandated by the study protocol. Primary PCI was conducted
after expeditious transfer from the point of randomization, and
early initiation of aspirin, clopidogrel, and antithrombotic
therapy, including discretionary glycoprotein IIb/IIIa (GP 2b/
3a) antagonists based on best standard practice.
ECGs were performed at baseline, 90 minutes post-TNK,
and 30 minutes postcatheterization in the pharmacoinvasive
arm (including post-PCI in those undergoing PCI) and baseline
and 30 minutes postcatheterization or post-PCI (if performed)
in the primary PCI arm. Interpretation was performed at the
Canadian VIGOUR Center ECG Core Laboratory (Edmonton,
Alberta, Canada), and, for this study, the prespeciﬁed ECG
metrics included: worst lead ST-elevation resolution; worst
lead ST-elevation resolution ≥50%; and worst lead residual ST-
elevation. Both worst lead ST-elevation resolution and worst
lead residual ST-elevation have previously been shown to have
prognostic utility in STEMI patients undergoing primary PCI.18
Interventional cardiologists in participating sites deter-
mined the choice of the arterial access, either RA or FA based
upon local practice (Table S1). Angiographic assessment
detailing coronary anatomy, need for percutaneous interven-
tion after diagnostic angiography and Thrombolysis In
Myocardial Infarction (TIMI) ﬂow grade post-PCI was per-
formed locally by site-speciﬁc investigators using standard
deﬁnitions.19 Management of the arterial sheath postangiog-
raphy was also determined by site-speciﬁc vascular access
best practice protocols. The results of the current report are
based on the per-protocol analysis according to the access
site utilized to complete the angiographic procedure.
The primary outcome of this study was a 30-day composite
of death, cardiogenic shock, CHF, or reinfarction whereas the
key secondary outcomes included components of the primary
outcome at 30 days, nonintracranial major bleeding or ICH,
stroke, and 1-year all-cause mortality.
Detailed deﬁnitions for both the components of the
primary composite and bleeding endpoints have been pub-
lished previously.17 Brieﬂy, a stroke review independent panel
adjudicated all strokes centrally. The Global Use of Strategies
to Open Occluded Arteries (GUSTO) deﬁnition of bleeding20
was implemented in this trial. Major bleeding was classiﬁed
as: (1) intracranial or (2) nonintracranial—severe bleed (bleed
that leads to hemodynamic compromise requiring intervention
[blood or ﬂuid replacement, inotropic support, ventricular
assist device, or surgical repair] or life-threatening or fatal
bleed) or moderate bleed (bleeding requiring blood transfu-
sion, but that does not lead to hemodynamic compromise
requiring intervention). All bleeds, excluding intracranial
bleeds, were investigator reported. Access-site–related major
bleeding was deﬁned as major bleeding that occurred less
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than 48 hours post-PCI. Major access-site vascular compli-
cation included development of a pseudoaneurysm or an
arteriovenous ﬁstula.
Statistical Analysis
Categorical variables are summarized as percentages and as
median (25th, 75th percentiles) for continuous variables.
Baseline characteristics and concomitant treatment are
reported according to access site (radial vs femoral) and
study treatment received. Differences between groups were
tested with the chi-square test (or Fisher’s exact test when
count was <5 for at least 1 cell) for categorical variables and
Wilcoxon rank-sum test for continuous variables, respectively.
The association between access site and primary clinical
outcome (composite of death, cardiogenic shock, CHF, or
reinfarction) within 30 days was examined using a univariable
logistic regression model where a propensity score for access
site was used to construct an inverse probability weight.21
Given the assignment of access site was not randomized, a
propensity score for access site was created using a
multivariable logistic regression model. Variables considered
in the model were based on literature review, expert opinion,
and univariate tests with P<0.10. The covariates in the ﬁnal
model were forced in; that is, no conventional statistical
selection techniques (eg, stepwise, forward, or backward)
were used. Variables included in the ﬁnal propensity score
model were age, sex, weight, history of hypertension, history
of diabetes mellitus, heart rate, systolic blood pressure, Killip
class, inferior myocardial infarction (MI), sum ST elevation at
baseline, Q waves at baseline, time from symptom onset to
randomization, and country of enrollment (Table S2). The
interaction between access site and study treatment (ie, PI vs
pPCI) on the 30-day primary clinical composite outcome was
also examined. A further prespeciﬁed similar subgroup
analysis of access site within the PI (rescue vs scheduled)
strategy was performed.
To test whether GP 2b/3a use and protocol amendment
modulate the association between access site and 30-day
primary outcomes, the interaction between GP 2b/3a use and
access site and the interaction between protocol amendment
and access site were examined. Odds ratios (ORs) with 95%
CIs are reported. All statistical tests were 2-sided, with
P<0.05 considered as statistically signiﬁcant. Statistical
analyses were performed using SAS software (version 9.4;
SAS Institute Inc., Cary, NC).
Results
Baseline Characteristics
Figure 1 illustrates the 2 treatment group cohorts from the
1820 per-protocol treated patients enrolled in STREAM
categorized by access site. As evident, there was comparable
utilization of either access site within each treatment strategy
(FA: PI 53.4% [n=478] and pPCI 57.6% [n=533]). In addition,
within the PI strategy, both access sites were comparably
distributed in the rescue (FA: 52.8%; n=200) and scheduled
PCI (FA: 53.9%; n=278) subgroups.
Overall, STEMI patients treated by FA were younger, had
more past hypertension, lower systolic BP at presentation,
lower TIMI Risk Score, and more ST-elevation on the baseline
Randomized Full Analysis Set 
(n=1892)
FA
n=533
PI
n=895
pPCI
n=925
Patients excluded:
1.No disease of interest n=26
2.Did not undergo cath n=43
3. Access site information not 
available n=3
RA
n=392
FA
n=478
RA
n=417
Figure 1. Study patients’ ﬂow chart. FA indicates femoral; PI, pharmacoinvasive; pPCI,
primary percutaneous coronary intervention; RA, radial.
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ECG compared to the RA group (Table 1). These ﬁndings were
consistent within both PI and pPCI patients.
As described in Table 2, patients treated by FA had shorter
time from symptom onset to randomization in both treatment
strategies. In addition, shorter times from symptom onset to
femoral, compared to radial sheath, insertion were observed
in the pPCI, but not in the PI, strategy.
A signiﬁcantly higher utilization of GP2b/3a inhibitor use
was noted in the RA, compared to FA, group (40.2% vs 24.1%;
P<0.001), particularly in those undergoing pPCI. Those
patients treated with pPCI strategy and RA had higher rates
of post-PCI TIMI-3 ﬂow grade than FA patients. Evaluation of
the post-treatment ECG revealed consistently better indices
of reperfusion for patients with RA in both the PI and pPCI
cohorts, as evidenced by higher rates of worst lead residual
ST elevation <1 mm and lesser rates in patients with ≥2 mm
residual ST elevation.
Primary Outcome
Irrespective of treatment strategy, the unadjusted primary
composite of 30-day death, shock, CHF, or reinfarction
occurred in 8.9% in the RA compared to 15.7% in FA group
(Table 3). After adjustment, the beneﬁt favoring RA persisted
(adjusted OR, 0.59; 95% CI, 0.44–0.78; P<0.001), as seen in
Figure 2.
Analysis of access site categorized by study treatment
received revealed that the advantage associated with RA
was present in both the pPCI (adjusted OR, 0.63; 95% CI,
0.43–0.92) and PI cohorts (adjusted OR, 0.57; 95% CI,
0.37–0.86; P [interaction]=0.730; Figure 2). Within the PI
group, a trend for RA advantage was evident in the high-
risk rescue PCI (13.4% vs 26.3%; adjusted OR, 0.65; 95%
CI, 0.39–1.07) subgroup with no signiﬁcant difference in
patients undergoing scheduled PCI (5.5% vs 5.4%; adjusted
Table 1. Selected Baseline Patient Characteristics According to Access Site and Study Treatment
All PI pPCI
RA FA P Value RA FA P Value RA FA P Value
N 809 1011 417 478 392 533
Age, y 60 (52, 71) 58 (50, 66) <0.001 60 (52, 71) 58 (50, 65) 0.001 60 (52, 70) 58 (51, 66) 0.024
Female sex,
n (%)
161 (19.9) 214 (21.2) 0.507 80 (19.2) 93 (19.5) 0.918 81 (20.7) 121 (22.7) 0.458
Hypertension,
n (%)
343 (42.8) 472 (47.7) 0.038 188 (45.4) 227 (48.5) 0.358 155 (39.9) 245 (46.9) 0.036
Diabetes
mellitus,
n (%)
99 (12.3) 129 (12.9) 0.698 52 (12.5) 58 (12.3) 0.923 47 (12.1) 71 (13.5) 0.535
Heart rate,
bpm
73 (63, 84) 75 (62, 86) 0.434 73 (61, 85) 75 (62, 86) 0.147 75 (65, 83) 75 (62, 85) 0.670
Systolic blood
pressure,
mm Hg
139 (122, 156) 130 (120, 150) <0.001 138 (122, 152) 130 (120, 150) 0.002 140 (123, 157) 134 (120, 150) 0.004
Killip class
>I, n (%)
49 (6.2) 49 (5.3) 0.402 27 (6.6) 25 (5.7) 0.600 22 (5.8) 24 (4.9) 0.541
TIMI Risk
Score ≥5,
n (%)
120 (15.4) 97 (10.8) 0.005 61 (15.1) 44 (10.5) 0.048 59 (15.8) 53 (11.1) 0.045
Inferior MI*,
n (%)
402 (50.2) 506 (50.7) 0.845 212 (50.8) 230 (48.9) 0.572 190 (49.5) 276 (52.2) 0.421
Baseline STE
at worst
lead*, mm
3 (2, 4) 3 (2, 4) 0.029 3 (2, 4) 3 (2, 5) 0.194 3 (2, 4) 3 (2, 4) 0.063
Q wave in the
infarct
territory at
baseline*,
n (%)
251 (31.6) 325 (32.7) 0.624 132 (32.0) 154 (32.8) 0.782 119 (31.2) 171 (32.5) 0.665
Continuous variables presented as median (25th–75th percentiles). FA indicates femoral; MI, myocardial infarction; pPCI, primary percutaneous coronary intervention; RA, radial; STE, ST-
segment elevation; TIMI, Thrombolysis In Myocardial Infarction.
*Evaluated by ECG Core Laboratory at the Canadian VIGOUR Centre.
DOI: 10.1161/JAHA.116.003559 Journal of the American Heart Association 4
Insights From the STREAM Study Shavadia et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 17, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Ta
bl
e
2.
Is
ch
em
ic
Ti
m
es
,
M
ed
ic
at
io
ns
,
An
gi
og
ra
ph
ic
Fi
nd
in
gs
,
an
d
Po
st
-T
re
at
m
en
t
EC
G
Ac
co
rd
in
g
to
Ac
ce
ss
Si
te
an
d
St
ud
y
Tr
ea
tm
en
t
Al
l
PI
pP
C
I
RA
FA
P
Va
lu
e
RA
FA
P
Va
lu
e
RA
FA
P
Va
lu
e
N
80
9
10
11
41
7
47
8
39
2
53
3
Is
ch
em
ic
tim
es
Sy
m
pt
om
on
se
t
to
ra
nd
om
iz
at
io
n,
m
in
96
(6
9,
14
0)
88
(6
3,
12
6)
<
0.
00
1
95
(6
8,
14
2)
89
(6
5,
12
4)
0.
01
2
97
(7
0,
13
8)
88
(6
1,
12
7)
0.
00
7
Sy
m
pt
om
on
se
t
to
TN
K,
m
in
—
—
—
10
5
(7
9,
15
0)
97
(7
4,
13
5)
0.
00
1
—
—
—
Sy
m
pt
om
on
se
t
to
sh
ea
th
in
se
rti
on
,
m
in
—
—
—
62
4
(2
60
,
13
20
)
61
6
(2
68
,
12
18
)
0.
29
6
18
5
(1
53
,
24
0)
17
0
(1
25
,
22
5)
0.
00
1
M
ed
ic
at
io
ns
GP
2b
/3
a
gi
ve
n,
n
(%
)
32
5
(4
0.
2)
24
4
(2
4.
1)
<
0.
00
1
44
(1
0.
6)
36
(7
.5
)
0.
11
4
28
1
(7
1.
7)
20
8
(3
9.
0)
<
0.
00
1
Cl
op
id
og
re
lg
iv
en
,
n
(%
)
71
3
(8
8.
4)
94
9
(9
4.
4)
<
0.
00
1
36
2
(8
7.
2)
45
1
(9
5.
6)
<
0.
00
1
35
1
(8
9.
5)
49
8
(9
3.
4)
0.
03
3
Un
fra
ct
io
na
te
d
he
pa
rin
,
n
(%
)
52
5
(6
4.
9)
51
7
(5
1.
1)
<
0.
00
1
24
2
(5
8.
0)
11
5
(2
4.
1)
<
0.
00
1
28
3
(7
2.
2)
40
2
(7
5.
4)
0.
26
8
An
gi
og
ra
ph
ic
M
ul
tiv
es
se
ld
is
ea
se
,
n
(%
)
35
8
(4
6.
3)
45
2
(4
6.
7)
0.
87
4
18
4
(4
6.
2)
22
6
(4
8.
7)
0.
46
8
17
4
(4
6.
4)
22
6
(4
4.
8)
0.
64
6
Pa
tie
nt
s
re
ce
iv
in
g
PC
I,
n
(%
)
68
9
(8
5.
2)
88
5
(8
7.
5)
0.
14
2
34
1
(8
1.
8)
38
5
(8
0.
5)
0.
63
9
34
8
(8
8.
8)
50
0
(9
3.
8)
0.
00
6
Po
st
-P
CI
TI
M
IF
lo
w
Gr
ad
e,
n
(%
)
0.
12
1
0.
49
5
0.
03
6
0/
1
16
(2
.4
)
27
(3
.1
)
11
(3
.3
)
9
(2
.4
)
5
(1
.5
)
18
(3
.7
)
2
20
(3
.0
)
41
(4
.8
)
12
(3
.6
)
19
(5
.1
)
8
(2
.3
)
22
(4
.5
)
3
64
0
(9
4.
7)
79
1
(9
2.
1)
31
0
(9
3.
1)
34
2
(9
2.
4)
33
0
(9
6.
2)
44
9
(9
1.
8)
Po
st
-t
re
at
m
en
t
EC
G*
W
or
st
-le
ad
ST
-e
le
va
tio
n
re
so
lu
tio
n,
%
75
(5
0,
10
0)
71
(5
0,
10
0)
0.
47
2
67
(3
3,
10
0)
67
(3
3,
10
0)
0.
48
6
78
(5
7,
10
0)
75
(5
0,
10
0)
0.
03
2
W
or
st
-le
ad
ST
-e
le
va
tio
n
re
so
lu
tio
n
≥5
0%
,
n
(%
)
64
2
(8
6.
8)
76
9
(8
3.
7)
0.
08
0
33
3
(8
7.
4)
37
0
(8
7.
5)
0.
97
7
30
9
(8
6.
1)
39
9
(8
0.
4)
0.
03
1
W
or
st
-le
ad
re
si
du
al
ST
-e
le
va
tio
n,
n
(%
)
<
0.
00
1
0.
01
9
0.
00
1
<
1
m
m
36
4
(4
8.
3)
35
5
(3
8.
2)
20
5
(5
3.
4)
18
8
(4
3.
9)
15
9
(4
3.
0)
16
7
(3
3.
3)
1
to
<
2
m
m
26
7
(3
5.
4)
35
0
(3
7.
7)
12
7
(3
3.
1)
16
1
(3
7.
6)
14
0
(3
7.
8)
18
9
(3
7.
7)
≥2
m
m
12
3
(1
6.
3)
22
4
(2
4.
1)
52
(1
3.
5)
79
(1
8.
5)
71
(1
9.
2)
14
5
(2
8.
9)
C
on
tin
uo
us
va
ria
bl
es
pr
es
en
te
d
as
m
ed
ia
n
(2
5t
h–
75
th
pe
rc
en
til
es
).
P
fo
r
co
m
pa
ris
on
be
tw
ee
n
RA
an
d
FA
gr
ou
ps
.E
C
G
in
di
ca
te
s
el
ec
tr
oc
ar
di
og
ra
m
;F
A,
fe
m
or
al
;G
P,
gl
yc
op
ro
te
in
;I
AB
P,
in
tr
a-
ao
rt
ic
ba
llo
on
pu
m
p;
pP
C
I,
pr
im
ar
y
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n;
RA
,
ra
di
al
;
TI
M
I,
Th
ro
m
bo
ly
si
s
In
M
yo
ca
rd
ia
lI
nf
ar
ct
io
n;
TN
K,
te
ne
ct
ep
la
se
.
*E
va
lu
at
ed
by
EC
G
C
or
e
La
bo
ra
to
ry
at
th
e
C
an
ad
ia
n
VI
G
O
U
R
C
en
te
r.
DOI: 10.1161/JAHA.116.003559 Journal of the American Heart Association 5
Insights From the STREAM Study Shavadia et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 17, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
OR, 0.55; 95% CI, 0.24–1.26). However, no interaction
was evident between rescue PCI or scheduled PCI as
it relates to the advantage of RA after adjustment
(P [interaction]=0.739).
The observed increase in GP 2b/3a use within the RA
group did not appear to modulate the association with the 30-
day primary composite outcome (RA: GP 2b/3a use vs not,
9.3% versus 8.7%; and FA: 20.2% vs 14.3%; P [interaction]
=0.988); neither did the implementation of the amendment
(half-dose lytic in patients ≥75 years) of the STREAM trial
protocol (RA and FA: pre- and postamendment, respectively,
9.0% vs 8.9% and 18.4% vs 15.2%; P [interaction]=0.920). The
increased GP 2b/3a use within the RA group also did not
appear to modulate the association with major bleeding (RA
vs FA: adjusted hazard ratio, 0.56; 95% CI, 0.28–1.12; P
[interaction]=0.087).
Secondary Outcomes
Radial access was associated with an observed reduction in
30-day mortality (2.4% vs 4.7%; P=0.009), cardiogenic shock
(2.9% vs 6.4%; P=0.001), and heart failure (5.0% vs 8.4%;
P=0.005; Table 3). No signiﬁcant differences in ischemic
stroke or ICH were noted in either vascular access site across
the 2 treatment groups. At 1 year, no difference in all-cause
mortality was noted in either access-site category across both
study treatment groups.
Major Bleeding
Overall, a comparable rate of nonintracranial major bleeding
was noted in the RA versus FA group (5.2% vs 6.0%; P=0.489;
Table 3). This was also evident within the 2 treatment
strategies (PI and pPCI: RA vs FA, 5.5% vs 7.8% [P=0.179] and
4.9% vs 4.3% [P=0.698], respectively); however, within the PI
strategy, a trend to increased nonintracranial major bleeding
in patients treated by FA within the rescue, compared to the
scheduled, subgroup was observed (rescue and scheduled: RA
vs FA, 6.1% vs 11.6% [P=0.064] and 5.1% vs 5.1% [P=0.996]).
Both major access-site (RA vs FA, 2.8% vs 4.1%; P=0.163) and
non-access-site (RA vs FA, 2.3% vs 1.9%; P=0.487) bleeding
were similarly distributed in the overall study population.
Major vascular access complication (pseudoaneurysm or
arteriovenous ﬁstula development) occurred in 0% in the RA
and 1.4% in the FA group.
Discussion
The results of this study indicate that in early presenting STEMI
(<3 hours from symptom onset), utilization of RA over FA is
associated with a signiﬁcant reduction in the composite of
major adverse cardiovascular events regardless of the appli-
cation of a ﬁbrinolytic PI or pPCI strategy. In addition, within the
PI strategy, the prognostic advantage of RA applies particularly
to the higher risk rescue PCI cohort in whom a doubling of
Table 3. Efﬁcacy and Safety Outcomes According to Access Site and Study Treatment
All PI pPCI
RA FA P Value RA FA P Value RA FA P Value
N 809 1011 417 478 392 533
30 days
Primary composite endpoint:
death/CHF/shock/reinfarction,
n (%)
72 (8.9) 158 (15.7) <0.001 37 (8.9) 67 (14.1) 0.016 35 (9.0) 91 (17.2) <0.001
All-cause death, n (%) 19 (2.4) 47 (4.7) 0.009 9 (2.2) 23 (4.8) 0.032 10 (2.6) 24 (4.5) 0.119
Cardiogenic shock, n (%) 23 (2.9) 64 (6.4) 0.001 11 (2.6) 27 (5.7) 0.025 12 (3.1) 37 (7.0) 0.009
CHF, n (%) 40 (5.0) 84 (8.4) 0.005 19 (4.6) 36 (7.6) 0.062 21 (5.4) 48 (9.1) 0.037
Reinfarction, n (%) 15 (1.9) 26 (2.6) 0.302 11 (2.6) 10 (2.1) 0.600 4 (1.0) 16 (3.0) 0.041
Total strokes, n (%) 9 (1.1) 7 (0.7) 0.342 6 (1.4) 5 (1.1) 0.599 3 (0.8) 2 (0.4) 0.424
Intracranial hemorrhage, n (%) 5 (0.6) 2 (0.2) 0.150 4 (1.0) 2 (0.4) 0.323 1 (0.3) 0 (0.0) 0.243
Nonintracranial bleeding,
major, n (%)
42 (5.2) 60 (6.0) 0.489 23 (5.5) 37 (7.8) 0.179 19 (4.9) 23 (4.3) 0.698
Access-site–related major
bleeding, n (%)
23 (2.8) 41 (4.1) 0.163 12 (2.9) 23 (4.8) 0.137 11 (2.8) 18 (3.4) 0.622
1 year
All-cause death, n (%) 37 (4.6) 63 (6.3) 0.125 21 (5.1) 30 (6.3) 0.418 16 (4.1) 33 (6.2) 0.163
CHF indicates congestive heart failure; pPCI, primary percutaneous coronary intervention.
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adverse outcomes appeared evident within the femoral access
subgroup.
Within the STREAM study at baseline, patients treated by FA
were more hypotensive and had greater ST elevation at
presentation, reﬂective of adverse outcomes. Given this clinical
proﬁle, it is reasonable to suppose that thismay have inﬂuenced
the choice of FA and subsequently be reﬂected in worse
outcomes. However, even after adjustment, the RA 30-day
composite clinical outcomes andmortality advantage persisted.
The STREAM study enrolled patients presenting within
3 hours of symptom onset and thus represents a very early
presenting STEMI population as compared to other trials that
randomized access site in STEMI patients (12–24 hours).2,3,7
Hence, this study evaluated a distinct STEMI cohort undergoing
early cardiac catheterizations (except for scheduled PCI cohort)
in the presence of potent antiantithrombotic and ﬁbrinolytic
agents. It would therefore seem that lower major bleeding
would be associated with the observed signiﬁcant reduction in
the primary composite and 30-day mortality favoring RA across
both treatment strategies. Although there was nominally less
nonintracranial major access-site and non-access-site bleeding
in those pharmacoinvasive-treated patients undergoing RA,
this was not statistically signiﬁcant. Apart from lower major
bleeding, the mechanism by which radial access might relate to
all-cause mortality currently remains unclear in the existing
literature.13,22 One plausible explanation for the observed
prognostic difference favoring RA relates to selection bias
introduced by operator experience and center-speciﬁc differ-
ences. Greater radial interventional expertise in high-volume
centers may have been associated with improved outcomes
resulting from reduced vascular complications.
To provide some context, it is noteworthy that 50% of the
patients analyzed in the current study were treated with a
ﬁbrinolytic PI strategy, as compared to a much lower
incidence in the Radial Versus Femoral Randomized Investi-
gation in ST-Elevation Acute Coronary Syndrome (RIFLE
STEACS; 7.6% failed ﬁbrinolysis)2 and Radial versus femoral
access for coronary intervention (RIVAL; 12%)7 trials. Hence,
the current results not only support the effectiveness of RA
within a PI-treated STEMI patient subset, but also allow
comparison of outcomes between roughly equal-sized groups
undergoing different reperfusion strategies.
Compared to randomized trials that enrolled postﬁbri-
nolytic patients,2,7 a higher proportion of major overall and
0.0 1.0 2.0
Irrespective of treatment strategy
<0.001
P value
0.730
72/806(8.9) 158/1005(15.7) 0.59(0.44-0.78)
0.57(0.37-0.86)
0.63(0.43-0.92)
RA versus FA
PI
37/416(8.9) 67/475(14.1)
pPCI
35/390(9.0) 91/530(17.2)
Adjusted
OR(95%CI)
FA BetterRA Better
RA versus FA
RA versus FA
P value (interaction)
No. of events/total no. of patients  (%)
(n=809) (n=1011) 
RA                           FA
Figure 2. Upper panel: association between access site and primary endpoints irrespective of treatment strategy. Lower panel: association
between access site and primary endpoints according to treatment strategy. Odds ratio (OR) was propensity score adjusted as an inverse
probability weight. FA indicates femoral; PI, pharmacoinvasive; pPCI, primary percutaneous coronary intervention; RA, radial.
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major access-site bleeding was noted in the current study; for
instance, radial versus femoral, respectively, in RIVAL,7 non–
coronary artery bypass graft major bleeding (RIVAL deﬁnition)
was noted in 0.84% versus 0.91%, whereas in RIFLE-STEACS
(TIMI deﬁnition) 1.8% versus 2.8% compared to 5.2% and 6.0%
in our study. The reasons for this disparity in major bleeding is
unclear, but could relate to: (1) investigator—rather than
central adjudication—of major bleeding in the current study;
(2) heterogeneity in deﬁnition of major bleeding; (3) differ-
ences in the proportion of the postﬁbrinolytic STEMI popu-
lation; and (4) variability in operator expertise and site-speciﬁc
vascular access protocols. Despite no difference in nonin-
tracranial major bleeding between the 2 access sites in this
study, our adjusted analysis of 30-day mortality showed a
persisting beneﬁt associated with the radial approach. It is
noteworthy that a recent study from the National Cardiovas-
cular Data Registry’s CathPCI Registry on bleeding complica-
tions in ﬁbrinolytic-treated patients undergoing rescue PCI
reported a major bleeding rate of 6.9% in radial versus 12.0%
femoral access patients (adjusted OR, 0.67; 95% CI, 0.52–
0.87; P=0.003).23 RA was employed in only 16% of these
patients, and the authors highlighted the need for further data
in this “understudied high-risk group.”
Our study has both limitations and strengths. Given that
the choice of vascular access site was left to investigator
discretion and absence of access to detailed procedural
elements, we cannot exclude the impact of unmeasured
confounders. Additionally, selection bias introduced by
absence of information on center- and operator-speciﬁc
interventional volumes cannot be excluded. Although we
found no overall difference in vascular access bleeding, the
trend toward more FA access bleeding in the PI patients
undergoing rescue PCI suggests less bleeding hazard in the
presence of recent ﬁbrinolytic treatment when radial access is
employed. STREAM excluded patients in cardiogenic shock
and advanced kidney disease: Hence, our ﬁndings do not
apply to this population. Given that STREAM was an open-
label trial without central adjudication of bleeding endpoints,
investigator bias may have played a role in the disparity in
bleeding rates between this study and existing literature.
However, to the best of our knowledge, it is the largest
data set comparing a randomized, multicenter ﬁbrinolytic PI
strategy (rescue and scheduled PCI) in a very early-treated
STEMI population to pPCI, demonstrating that the outcomes
advantage with RA occurs in both the PI and pPCI strategy.
Conclusion
Irrespective of whether a pPCI or PI reperfusion strategy is
used, these results support the utilization of radial access as
the preferred arterial access site in STEMI.
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Table S1. Radial vs. Femoral access according to country of enrollment. 
 
Country n RA FA 
 1820 809(44.5) 1011(55.5) 
Austria, n(%) 50 8 (16.0) 42 (84.0) 
Belgium, n(%) 7 0 (0.0) 7 (100.0) 
Brazil, n(%) 75 22 (29.3) 53 (70.7) 
Canada, n(%) 88 47 (53.4) 41 (46.6) 
France, n(%) 717 544 (75.9) 173 (24.1) 
Germany, n(%) 54 13 (24.1) 41 (75.9) 
Greece, n(%) 72 3 (4.2) 69 (95.8) 
Italy, n(%) 25 18 (72.0) 7 (28.0) 
Norway, n(%) 53 45 (84.9) 8 (15.1) 
Peru, n(%) 2 0 (0.0) 2 (100.0) 
Poland, n(%) 27 18 (66.7) 9 (33.3) 
Russia, n(%) 306 11 (3.6) 295 (96.4) 
Serbia, n(%) 128 6 (4.7) 122 (95.3) 
Spain, n(%) 159 34 (21.4) 125 (78.6) 
United Kingdom, n(%) 57 40 (70.2) 17 (29.8) 
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Table S2. Logistic regression model (propensity score model) of access site and 
baseline characteristics. 
Variables Degree of 
freedom 
Wald p-values 
Age, year 1 0.05 0.830 
Female 1 0.02 0.884 
Weight, kg 1 4.44 0.035 
History of hypertension 1 1.93 0.164 
History of diabetes 1 0.11 0.742 
Heart rate, bpm 1 4.50 0.034 
Systolic blood pressure, mmHg 1 3.54 0.060 
Killip class > I 1 4.04 0.044 
Inferior MI 1 0.74 0.390 
Sum ST elevation at baseline, mm 1 0.10 0.753 
Q waves at baseline 1 0.50 0.479 
Time from symptom onset to 
randomization, hour 
1 4.97 0.026 
Country of enrolment   14 460.17 <0.001 
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Countries and Investigators 
 
In addition to the authors, the following investigators participated in the STREAM 
study: 
 
Austria (52 patients): A Kaff, R Malzer, D Sebald, D Glogar, M Gyöngyösi, F 
Weidinger, H Weber, G Gaul, F Chmelizek, S Seidl, M Pichler, I Pretsch. 
Belgium (7 patients): M Vergion, M Herssens, C Van Haesendonck.  
Brazil (79 patients): JFK Saraiva, ALF Sparenberg, JA Souza, JBM Moraes, FM 
Sant’anna, E Tarkieltaub, JR Hansen, EM Oliveira, O Leonhard. 
Canada (92 patients): W Cantor, M Senaratne.  
France (751 patients): E Aptecar, P Asseman, L Belle, O Belliard, J Berland, A 
Berthier, C Besnard, A Bonneau, E Bonnefoy, M Brami, G Canu, G Capellier, S Cattan, 
D Champagnac, P Chapon, B Cheval, J Claudel, P Cohen Tenoudji, P Coste, V Debierre, 
R Domergue, K Echahed, C El Khoury, E Ferrari, P Garrot, P Henry, B Jardel, R Jilwan, 
V Julie, R Ketelers, F Lapostolle, J Le Tarnec, B Livarek, Y Mann, X Marchand, F Pajot, 
T Perret, P Petit, V Probst, A Ricard Hibon, C Robin, A Salama, E Salengro, D Savary, F 
Schiele, L Soulat, X Tabone, P Taboulet, M Thicoïpe, J Torres, C Tron, G Vanzetto, L 
Villain-Coquet. 
Germany (58 patients): S Piper, HC Mochmann, L Nibbe, U Schniedermeier, H Heuer, 
F Marx, W Schöls, W Lepper, R Grahl, G Muth. 
Greece (76 patients): G Lappas, I Mantas, E Skoumbourdis, C Dilanas, I Kaprinis, I 
Vogiatzis, I Zarifis, G Spyromitros, S Konstantinides, D Symeonides. 
Italy (25 patients): GP Rossi, F Bermano, S Ferlito, P Paolini, L Valagussa, F Della 
Rovere, F Miccoli, M Chiti, W Vergoni, M Comeglio, G Percoco, M Valgimigli. 
Norway (55 patients): K Berget, O Skjetne, H Schartum-Hansen, K Andersen, OJ 
Rolstad. 
Peru (3 patients): ON Aguirre Zurita, RP Castillo León, AC Villar Quiroz 
Poland (29 patients): A Glowka, P Kulus. 
Russian Federation (327 patients): S Kalinina, A Bushuev, O Barbarash, N Tarasov, I 
Fomin, E Makarov, V Markov, A Danilenko, E Volkova, A Frolenkov, N Burova, A 
 by guest on M
arch 17, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Yakovlev, L Elchinskaya, S Boldueva, G Klein, I Kolosova, E Ovcharenko, R Fairushin. 
Serbia (134 patients): S Andjelic, V Vukcevic, A Neskovic, M Krotin, T Rajkovic, M 
Pavlovic, J Perunicic, S Kovacevic, V Petrovic, V Mitov. 
Spain (167 patients): A Ruiz, A García-Alcántara, M Martínez, J Díaz, MA, Paz, FL 
Manzano, C Martín, C Macaya, E Corral, JJ Fernández, F Martín, R, García. 
United Kingdom (60 patients): N Siriwardena, O Rawstorne, A Baumbach, G 
Manoharan, I Menown, S McHechan, D Morgan. 
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